Drug Targets with Inhibitors Designed Using Structure-based Drug Discovery Methods

Published in reference R.C. Stevens. "The cost and value of three-dimensional protein structure" Drug Discovery World, 4, 35-48 (2003).

HIV protease bcl-2
renin neuraminidase
factor Xa glyceraldehyde-3-phosphate dehydrogenase
thrombin interleukin-1b-converting enzyme (ICE, caspase-1)
factor VIIa/TF thymidylate synthase
urokinase protein-tyrosine phosphatase
urokinase-type plasminogen activator acetylcholinesterase
rhinovirus 3C protease prostaglandin receptor
cathepsin B, L, and S matrix metalloproteinase (MMP)
20S proteasome (chymotrypsin-activity) trihydroxynaphthalene reductase (3HNR)
memapsin 2 (beta-secretase) dihydrofolate reductase (MAC vs human)
Abl kinase cyclooxygenase-2
CDKs neuronal nicotinic receptor agonists
EGFR kinase 5 a-reductase
Lck kinase monoamine oxidase-B
Src kinase N-myristoyl transferase
aldose reductase hypoxanthine-guanine-xanthine phosphoribosyltransferase
phospholipase-A2 DNA gyrase
STAT human carbonic anhydrase II
bcl-2 peptide deformylase
DPP4 HDAC

last updated December 18, 2003 - send corrections and comments to Angela Walker (alwalker@scripps.edu)